Canada's Zymeworks 2025 revenue rises 39%

Zymeworks

02/03/2026 11:08

Overview

Biotechnology firm's 2025 revenue rose 39% yr/yr, driven by clinical milestones

Net loss for 2025 reduced by 34% compared to previous year

Company utilized $62.5 mln for share repurchases under current program

Outlook

Zymeworks expects adjusted operating expenses in 2026 to be 20% lower than 2025

Company anticipates regulatory milestone payments to fund operations beyond 2028

Zymeworks remains focused on timely execution of its novel strategy in 2026

Result Drivers

MILESTONE ACHIEVEMENTS - Revenue growth in 2025 was primarily driven by significant clinical and regulatory milestones achieved through collaborations with partners such as J&J and BeOne

ROYALTY TRANSITION - Transition of zanidatamab clinical activities to Jazz expected to reduce development-support revenue but increase royalty revenue over time

ROYALTY-BACKED FINANCING - $250 mln royalty-backed note financing with Royalty Pharma to support share repurchases and potential acquisitions

Company press release: ID:nGNXc8SC3P

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Basic EPS
-$0.55
Q4 Operating Expenses
$46.67 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Zymeworks Inc is $34.00, about 46% above its February 27 closing price of $23.29

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)